Zacks Investment Research on MSN
Here's why you should add PacBio stock to your portfolio now
Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, has been gaining from its continued product ...
The latest analyst update for Pacific Biosciences of California cuts the rating to Underweight and trims the price target from US$2 to US$1.50, while keeping a fair value estimate of US$2.43 per share ...
StockStory.org on MSN
Azenta, 10x Genomics, PacBio, Oscar Health, and Moderna shares plummet, what you need to know
What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones ...
28d
PacBio, CONMED, Moderna, QuidelOrtho, and Tandem Diabetes Shares Are Falling, What You Need To Know
A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in ...
MENLO PARK, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced its entry into the ...
(RTTNews) - PacBio (PACB), a developer of highly accurate sequencing solutions, is slated to participate in several upcoming investor conferences this month, underscoring its visibility within the ...
MENLO PARK, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2025. Fourth quarter and full year ...
PacBio reports that through its partnership with China-headquartered Berry Genomics, the Sequel II CNDx system has received Class III Medical Device Registration approval from the National Medical ...
PacBio has announced its participation in the 1000 Genomes Long Read Sequencing Project, contributing long-read transcriptome data to enhance this significant human genomics initiative. Through ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results